Schizophrenia, Dyslipidemias
Conditions
Brief summary
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.
Interventions
Vildagliptin 50 MG tablet once daily
DRUGPlacebo
Placebo one tablet daily
Sponsors
Sadat City University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.
Exclusion criteria
* liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| low-density lipoprotein cholesterol | week 12 | low-density lipoprotein cholesterol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum stem cell growth factor beta | week 12 | Serum stem cell growth factor beta |
| high-density lipoprotein cholesterol | week 12 | high-density lipoprotein cholesterol |
| TNF-alpha serum level | 12 weeks | TNF-alpha serum level |
| Adverse drug reactions | 12 weeks | Adverse drug reactions |
| FAM19A5 serum level | 12 weeks | FAM19A5 serum level |
Other
| Measure | Time frame | Description |
|---|---|---|
| body mass index | 12 weeks | body mass index |
Countries
Egypt
Outcome results
None listed